| 摘要 |
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or 5 prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, . benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyperand normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block 10 prolactin receptor-mediated signaling. |
